Next Article in Journal
Modification of Magnetite Nanoparticles with Triazine-Based Dendrons and Their Application as Drug-Transporting Systems
Previous Article in Journal
LegumeSSRdb: A Comprehensive Microsatellite Marker Database of Legumes for Germplasm Characterization and Crop Improvement
Previous Article in Special Issue
Genomic Biomarkers of Meningioma: A Focused Review
Review

Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma

1
Department of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre 90050-170, Brazil
2
Experimental Research Center, Cancer and Neurobiology Laboratory, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre 90035-003, Brazil
3
Epigenica Biosciences, Canoas 92035-000, Brazil
4
Graduate Program in Surgery, Mackenzie Evangelical University of Paraná (FEMPAR), Curitiba 80730-000, Brazil
5
The Center for Advanced Neurology and Neurosurgery (CEANNE)-Brazil, Porto Alegre 90050-170, Brazil
*
Author to whom correspondence should be addressed.
Academic Editor: Tianhua Niu
Int. J. Mol. Sci. 2021, 22(21), 11352; https://doi.org/10.3390/ijms222111352
Received: 25 August 2021 / Revised: 7 October 2021 / Accepted: 9 October 2021 / Published: 21 October 2021
(This article belongs to the Special Issue Biomarkers for Meningioma)
Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years, providing a rational basis for the identification of biomarkers and therapeutic targets. The role of receptor tyrosine kinases (RTKs) as oncogenes, including those of the ErbB family of receptors, has been well established in several cancer types. Here, we review histological, molecular, and clinical evidence suggesting that RTKs, including the epidermal growth factor receptor (EGFR, ErbB1), as well as other members of the ErbB family, may be useful as biomarkers and therapeutic targets in MGM. View Full-Text
Keywords: epidermal growth factor receptor; ErbB; biomarker; meningioma; intracranial tumor epidermal growth factor receptor; ErbB; biomarker; meningioma; intracranial tumor
Show Figures

Figure 1

MDPI and ACS Style

Roesler, R.; Souza, B.K.; Isolan, G.R. Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma. Int. J. Mol. Sci. 2021, 22, 11352. https://doi.org/10.3390/ijms222111352

AMA Style

Roesler R, Souza BK, Isolan GR. Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma. International Journal of Molecular Sciences. 2021; 22(21):11352. https://doi.org/10.3390/ijms222111352

Chicago/Turabian Style

Roesler, Rafael, Barbara K. Souza, and Gustavo R. Isolan 2021. "Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma" International Journal of Molecular Sciences 22, no. 21: 11352. https://doi.org/10.3390/ijms222111352

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop